Cancer Research CTRC-AACR San Antonio Breast Cancer Symposium  Tumor Immunology: New Perspectives
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 20, 1561-1572, December 1, 1960]
© 1960 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Klein, G.
Right arrow Articles by Hellström, K. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Klein, G.
Right arrow Articles by Hellström, K. E.

Demonstration of Resistance against Methylcholanthreneinduced Sarcomas in the Primary Autochthonous Host*

George Klein, Hans Olof Sjögren, Eva Klein and Karl Erik Hellström

( Institute for Tumor Biology, Karolinska Institutet Medical School, Stockholm, Sweden)

Host resistance against methylcholanthrene (MC)-induced sarcomas, demonstrated by previous authors after transplantation to isologous recipients, could also be shown to occur in the primary autochthonous host, whose tumor had been operatively removed. The autochthonous mice, together with groups of isologous animals, were pretreated with irradiated sarcoma cells and subsequently challenged with increasing doses of viable cells, also inoculated into untreated isologous controls. An increased resistance could be demonstrated with twelve out of sixteen tumors in the autochthonous and nineteen out of 22 tumors in the isologous host. Resistance was relative rather than absolute and broke down when the dose of viable cells was progressively increased. It was usually stronger in isologous than in autochthonous mice, but this was not a general rule. Isologous mice pretreated with irradiated normal tissues and subsequently challenged with viable sarcoma cells showed either no increase in resistance or a slight increase that exceeded the control level but did not reach the level found in isologous hosts pretreated with irradiated cells of the same sarcoma. Isologous, untreated mice that had received total-body irradiation before being challenged with viable sarcoma cells supported the growth of small viable inocula better than did unirradiated isologous hosts.

In the cases tested, resistance against a given sarcoma did not lead to cross-resistance against a different sarcoma, induced in the same genotype by MC. Serial treatment with homologous, MC-induced sarcoma tissue did not reduce the yield of primary sarcomas obtained after application of MC.

Lymph node cells, but not serum, of isologous mice pretreated with heavily irradiated sarcoma cells, could neutralize the sarcoma cells wholly or partially upon incubation in vitro. Lymph node cells of untreated animals and preimmunized lymph node cells killed by freezing and thawing had no effect.

* This work has been supported by grants from the National Cancer Institute, U.S. Public Health Service, and by grants from the Swedish Cancer Society and Lotten Bohmans Fund. Our thanks are due to Miss Maj-Lis Eriksson and Miss Birgitta Pettersson for valuable technical assistance.

Received 5/27/60.


This article has been cited by other articles:


Home page
Cancer Res.Home page
N. H. Segal, D. W. Parsons, K. S. Peggs, V. Velculescu, K. W. Kinzler, B. Vogelstein, and J. P. Allison
Epitope Landscape in Breast and Colorectal Cancer
Cancer Res., February 1, 2008; 68(3): 889 - 892.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
O. J. Finn
Human Tumor Immunology at the Molecular Divide
J. Immunol., March 1, 2007; 178(5): 2615 - 2616.
[Full Text] [PDF]


Home page
J. Immunol.Home page
G. Parmiani, A. De Filippo, L. Novellino, and C. Castelli
Unique Human Tumor Antigens: Immunobiology and Use in Clinical Trials
J. Immunol., February 15, 2007; 178(4): 1975 - 1979.
[Abstract] [Full Text] [PDF]


Home page
ScienceHome page
P van der Bruggen, C Traversari, P Chomez, C Lurquin, E De Plaen, B Van den Eynde, A Knuth, and T Boon
A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma
Science, December 13, 1991; 254(5038): 1643 - 1647.
[Abstract] [PDF]


Home page
ScienceHome page
O. Stutman
Tumor Development after 3-Methylcholanthrene in Immunologically Deficient Athymic-Nude Mice
Science, February 8, 1974; 183(4124): 534 - 536.
[Abstract] [PDF]


Home page
ScienceHome page
I. D. Bernstein, D. E. Thor, B. Zbar, and H. J. Rapp
Tumor hnmunity: Tumor Suppression in vivo Initiated by Soluble Products of Specifically Stimulated Lymphocytes
Science, May 14, 1971; 172(3984): 729 - 731.
[Abstract] [PDF]


Home page
ScienceHome page
U. Kim
Metastasizing Mammary Carcinomas in Rats: Induction and Study of Their Immunogenicity
Science, January 2, 1970; 167(3914): 72 - 74.
[Abstract] [PDF]


Home page
ScienceHome page
I. Hellstrom and K. E. Hellstrom
Cell-Bound Immunity to Autologous and Syngeneic Mouse Tumors Induced by Methylcholanthrene and Plastic Discs
Science, May 19, 1967; 156(3777): 981 - 983.
[Abstract] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1960 by the American Association for Cancer Research.